149 related articles for article (PubMed ID: 34918300)
1. Humanized Patient-Derived Xenograft Models of Ovarian Cancer.
Gitto SB; George E; Medvedev S; Simpkins F; Powell DJ
Methods Mol Biol; 2022; 2424():255-274. PubMed ID: 34918300
[TBL] [Abstract][Full Text] [Related]
2. An autologous humanized patient-derived-xenograft platform to evaluate immunotherapy in ovarian cancer.
Gitto SB; Kim H; Rafail S; Omran DK; Medvedev S; Kinose Y; Rodriguez-Garcia A; Flowers AJ; Xu H; Schwartz LE; Powell DJ; Simpkins F
Gynecol Oncol; 2020 Jan; 156(1):222-232. PubMed ID: 31818495
[TBL] [Abstract][Full Text] [Related]
3. Humanized Patient-derived Xenograft Models of Disseminated Ovarian Cancer Recapitulate Key Aspects of the Tumor Immune Environment within the Peritoneal Cavity.
Steinkamp MP; Lagutina I; Brayer KJ; Schultz F; Burke D; Pankratz VS; Adams SF; Hudson LG; Ness SA; Wandinger-Ness A
Cancer Res Commun; 2023 Feb; 3(2):309-324. PubMed ID: 36860657
[TBL] [Abstract][Full Text] [Related]
4. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy for peritoneal ovarian carcinoma metastasis using ex vivo expanded tumor infiltrating lymphocytes.
Freedman RS; Platsoucas CD
Cancer Treat Res; 1996; 82():115-46. PubMed ID: 8849947
[TBL] [Abstract][Full Text] [Related]
6. Ex vivo expanded tumour-infiltrating lymphocytes from ovarian cancer patients release anti-tumour cytokines in response to autologous primary ovarian cancer cells.
Owens GL; Price MJ; Cheadle EJ; Hawkins RE; Gilham DE; Edmondson RJ
Cancer Immunol Immunother; 2018 Oct; 67(10):1519-1531. PubMed ID: 30039427
[TBL] [Abstract][Full Text] [Related]
7. Improving the cytotoxic response of tumor-infiltrating lymphocytes towards advanced stage ovarian cancer with an oncolytic adenovirus expressing a human vIL-2 cytokine.
Quixabeira DCA; Jirovec E; Pakola S; Havunen R; Basnet S; Santos JM; Kudling TV; Clubb JHA; Haybout L; Arias V; Grönberg-Vähä-Koskela S; Cervera-Carrascon V; Pasanen A; Anttila M; Tapper J; Kanerva A; Hemminki A
Cancer Gene Ther; 2023 Nov; 30(11):1543-1553. PubMed ID: 37666898
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy with B7H3-redirected bispecific antibody and Sorafenib elicits enhanced synergistic antitumor efficacy.
Huang C; Li H; Feng Y; Li X; Zhang Z; Jiang C; Wang J; Yang C; Fu Y; Mu M; Zhao S; Wang Z; Kuang Y; Hou H; Wang Y; Guo W; Xu J; Yang H; Zhou L; Tong A; Guo G
Theranostics; 2020; 10(23):10498-10512. PubMed ID: 32929362
[No Abstract] [Full Text] [Related]
9. Fidelity of human ovarian cancer patient-derived xenografts in a partially humanized mouse model for preclinical testing of immunotherapies.
Odunsi A; McGray AJR; Miliotto A; Zhang Y; Wang J; Abiola A; Eppolito C; Huang RY
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33177175
[TBL] [Abstract][Full Text] [Related]
10. Preclinical immunotherapy with Cytokine-Induced Killer lymphocytes against epithelial ovarian cancer.
Capellero S; Erriquez J; Melano C; Mesiano G; Genta S; Pisacane A; Mittica G; Ghisoni E; Olivero M; Di Renzo MF; Aglietta M; Sangiolo D; Valabrega G
Sci Rep; 2020 Apr; 10(1):6478. PubMed ID: 32296104
[TBL] [Abstract][Full Text] [Related]
11. Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics.
Liu JF; Palakurthi S; Zeng Q; Zhou S; Ivanova E; Huang W; Zervantonakis IK; Selfors LM; Shen Y; Pritchard CC; Zheng M; Adleff V; Papp E; Piao H; Novak M; Fotheringham S; Wulf GM; English J; Kirschmeier PT; Velculescu VE; Paweletz C; Mills GB; Livingston DM; Brugge JS; Matulonis UA; Drapkin R
Clin Cancer Res; 2017 Mar; 23(5):1263-1273. PubMed ID: 27573169
[No Abstract] [Full Text] [Related]
12. Patient-Derived Xenograft Models for Ovarian Cancer.
Tran TM; Ho GY; Chu S
Methods Mol Biol; 2024; 2806():187-196. PubMed ID: 38676803
[TBL] [Abstract][Full Text] [Related]
13. The latest animal models of ovarian cancer for novel drug discovery.
Magnotti E; Marasco WA
Expert Opin Drug Discov; 2018 Mar; 13(3):249-257. PubMed ID: 29338446
[TBL] [Abstract][Full Text] [Related]
14. Changes in ovarian tumor cell number, tumor vasculature, and T cell function monitored in vivo using a novel xenograft model.
Yokota SJ; Facciponte JG; Kelleher RJ; Shultz LD; Loyall JL; Parsons RR; Odunsi K; Frelinger JG; Lord EM; Gerber SA; Balu-Iyer SV; Bankert RB
Cancer Immun; 2013; 13():11. PubMed ID: 23885217
[TBL] [Abstract][Full Text] [Related]
15. Development of an Adrenocortical Cancer Humanized Mouse Model to Characterize Anti-PD1 Effects on Tumor Microenvironment.
Lang J; Capasso A; Jordan KR; French JD; Kar A; Bagby SM; Barbee J; Yacob BW; Head LS; Tompkins KD; Freed BM; Somerset H; Clark TJ; Pitts TM; Messersmith WA; Eckhardt SG; Wierman ME; Leong S; Kiseljak-Vassiliades K
J Clin Endocrinol Metab; 2020 Jan; 105(1):26-42. PubMed ID: 31513709
[TBL] [Abstract][Full Text] [Related]
16. Patient-Derived Xenograft Models of Epithelial Ovarian Cancer for Preclinical Studies.
Heo EJ; Cho YJ; Cho WC; Hong JE; Jeon HK; Oh DY; Choi YL; Song SY; Choi JJ; Bae DS; Lee YY; Choi CH; Kim TJ; Park WY; Kim BG; Lee JW
Cancer Res Treat; 2017 Oct; 49(4):915-926. PubMed ID: 28052650
[TBL] [Abstract][Full Text] [Related]
17. Ex vivo isolation, expansion and bioengineering of CCR7+CD95-/or CD62L+CD45RA+ tumor infiltrating lymphocytes from acute myeloid leukemia patients' bone marrow.
Cao H; Kim DH; Howard A; Moz H; Wasnik S; Baylink DJ; Chen CS; Reeves ME; Mirshahidi S; Xiao J; Francis O; Marcucci G; Xu Y
Neoplasia; 2021 Dec; 23(12):1252-1260. PubMed ID: 34775232
[TBL] [Abstract][Full Text] [Related]
18. Expanded CD56
Poznanski SM; Nham T; Chew MV; Lee AJ; Hammill JA; Fan IY; Butcher M; Bramson JL; Lee DA; Hirte HW; Ashkar AA
Cancer Immunol Res; 2018 Oct; 6(10):1174-1185. PubMed ID: 30018043
[TBL] [Abstract][Full Text] [Related]
19. Establishment and characterization of an ovarian yolk sac tumor patient-derived xenograft model.
Luo M; He Y; Xie B; Li S; Gan F; Zhang S; Luo P
Pediatr Surg Int; 2021 Aug; 37(8):1031-1040. PubMed ID: 34031745
[TBL] [Abstract][Full Text] [Related]
20. Establishment of humanized tumor microenvironment mouse models based on the injection of peripheral blood mononuclear cells and IFN-γ to evaluate the efficacy of PD-L1/PD-1-targeted immunotherapy.
Lin X; Zeng T; Lin J; Zhang Q; Cheng H; Fang S; Lin S; Chen Y; Xu Y; Lin J
Cancer Biol Ther; 2020; 21(2):130-138. PubMed ID: 31690181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
